GC Cell Affiliate Bioscentric Raises 38.2 Billion KRW in Series A Funding
GC Cell (GC Cell) announced on the 4th that its U.S. affiliate BioCentriq recently succeeded in raising a total of $29.2 million (approximately 38.2 billion KRW) in Series A funding. The sponsors related to this fundraising were not disclosed. The raised funds are planned to be used for strengthening cell therapy development and production facilities, investing in advanced technologies, and securing global professional talent.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- The Second Donghak Ant Movement? ... Individual Investors Keep Buying Despite Foreign Sell-Offs [1-Minute Brief]
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
James Park, CEO of GC Cell, who was appointed as the interim CEO of BioCentriq on the 1st, said, "I am very pleased that the trust of global investors in BioCentriq's vision and capabilities is reflected in the successful Series A funding." He added, "The funds raised through this funding are expected to enable us to provide innovative therapies to our partners and patients worldwide through continuous innovation in the field of cell therapy development."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
